Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery

Author(s): Rungsinee Phongpradist, Chuda Chittasupho, Siriporn Okonogi, Teruna Siahaan, Songyot Anuchapreeda, Chadarat Ampasavate, Cory Berkland.


Leukemia therapeutics are aiming for improved efficacy by targeting molecular markers differentially expressed on cancerous cells. Lymphocyte function-associated antigen-1 (LFA-1) expression on various types of leukemia has been well studied. Here, the role and expression of LFA-1 on leukemic cells and the possibility of using this integrin as a target for drug delivery is reviewed. To support this rationale, experimental results were also included where cIBR, a cyclic peptide derived from a binding site of LFA-1, was conjugated to the surface of polymeric nanoparticles and used as a targeting ligand. These studies revealed a correlation of LFA-1 expression level on leukemic cell lines and binding and internalization of cIBR-NPs suggesting a differential binding and internalization of cIBR-NPs to leukemic cells overexpressing LFA-1. Nanoparticles conjugated with a cyclic peptide against an accessible molecular marker of disease hold promise as a selective drug delivery system for leukemia treatment.

Keywords: HL-60 cell line, LFA-1, leukemia, Molt-3 cell line, Molt-4 cell line, peptide, nanoparticles, targeting, U937 cell line

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Year: 2010
Page: [2321 - 2330]
Pages: 10
DOI: 10.2174/138161210791920450
Price: $58